The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Under direction of Health Secretary Robert F. Kennedy Jr., the CDC is considering changes to its recommendations on vaccines ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV ... in order to protect their babies after birth found that the vaccine had efficacy of 81.8% in preventing lower ...

including data on co-administration with flu vaccines, as well as cost-effectiveness modelling. The agency sets the immunisation schedules for adults and children in the US. At stake is an RSV ...

Flu activity continues to ebb nationwide, with rates of influenza-like illness (ILI) dropping further last week, but ...

Animal and Plant Health Inspection Service (APHIS) has reported 6 more H5N1 avian flu detections in dairy cattle, all from ...

Arexvy is approved for use in the 50-59 age group, and Abrysvo is approved for use in all adults and in pregnant women as a way of protecting their infants from RSV vaccines ... of casting doubt on ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.